SINGAPORE, March 2, 2015 /PRNewswire/ -- Mundipharma today announced its planned distribution of Medifoam® in China starting early 2015, marking a key milestone in the company's plan to rapidly expand the innovative moist wound dressing product's reach in East Asia and South East Asia. Medifoam® was also launched recently in Malaysia, Thailand and Vietnam.
The Medifoam® foam range has the smallest compact micropore (opening) at the dressing contact layer that provides faster* wound healing and less pain during dressing change.1,2,3
One of the top products of its kind in South Korea, Medifoam® will be available in China in multiple foam dressing formats suitable for chronic wounds, burns and post-surgery wound care.
The expansion of the Medifoam® brand in China is part of a larger agreement signed by Mundipharma and Genewel in March 2014, for the licensing and marketing of Medifoam® moist wound dressing products by Mundipharma in Asia Pacific, the Middle East, Africa and Latin America.
"We are very happy to be bringing South Korea's leading wound treatment technology to the region. It will help elevate the quality of current wound care treatments available in China to another level," noted Peter Wang, General Manager, Greater China, Mundipharma.
"Medifoam® is our entrance into the consumer medical products space in China. While pain management remains our core business, we are excited to expand our offerings in the future, for example with our Betadine range of antiseptic products."
Raman Singh, President, Asia Pacific, Latin America, Middle East and Africa, Mundipharma also added that "Medifoam®'s expansion to China is a major step in our plans to better serve patients all over East Asia and South East Asia. Since its launches in South East Asia earlier this year we have significantly grown the reach of this innovative product from its original base in Korea and look forward to expanding it even further. "
*compared to Vaseline gauze and other foams
About Mundipharma
The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and rheumatoid arthritis.
For more information please visit: http://www.mundipharma.com.sg
Media Enquiries
Stephenie Vasko
Head of Communications -- Asia Pacific, Middle East, Africa and Latin America
Asia Pacific, Latin America, Middle East and Africa, Mundipharma
Email: Stephenie.vasko@mundipharma.com.sg
Tel: +65-6303-9732
Mobile: +65-8722-1846
Logo - http://photos.prnasia.com/prnh/20150302/8521501264LOGO